Check out our most popular compounded medications! Get Started
The Sirolimus 0.2% Topical Liquid is a specially crafted formulation intended for external application. This preparation is designed to deliver sirolimus directly to the skin or mucosal surfaces, providing localized treatment while minimizing systemic absorption and side effects.
This topical liquid is primarily used in the treatment of dermatological conditions such as psoriasis and atopic dermatitis, where it helps to reduce inflammation and immune response. Additionally, it is beneficial in the management of tuberous sclerosis complex-associated skin lesions, which include facial angiofibromas and ungual fibromas. The formulation may also be employed in the treatment of lymphangioleiomyomatosis, a rare lung disease, by direct application to the skin overlying the chest area.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Sirolimus 0.2% Topical Liquid is a specialized formulation intended for direct application to the skin or mucosal surfaces. This bespoke liquid preparation is designed to deliver sirolimus, an immunosuppressant drug that has been found to have various dermatological applications, to affected areas with precision.
The therapeutic benefits of Sirolimus 0.2% Topical Liquid are primarily its immunomodulatory and antiproliferative effects. Sirolimus, also known as rapamycin, works by inhibiting the mammalian target of rapamycin (mTOR) pathway, which plays a crucial role in cell growth, proliferation, and survival. By modulating this pathway, sirolimus can help manage conditions characterized by excessive cell growth or immune response. This includes, but is not limited to, the treatment of angiofibromas associated with tuberous sclerosis complex, psoriasis, and certain rare skin disorders such as lymphangioleiomyomatosis (LAM). It may also be beneficial in the management of cutaneous manifestations of graft-versus-host disease (GVHD) post organ transplantation.
For patients, the use of Sirolimus 0.2% Topical Liquid offers a targeted approach to treatment, potentially reducing the systemic side effects commonly associated with oral administration of immunosuppressants. This can be particularly advantageous for individuals who may be sensitive to systemic medications or those who require long-term management of their skin conditions. The topical route of administration also allows for ease of use and the ability to apply the medication directly to the affected area, providing localized relief.
Prescribers should consider the patient's overall medical condition and concomitant medications when recommending Sirolimus 0.2% Topical Liquid, as interactions and contraindications can exist. Monitoring for local skin reactions and adherence to the prescribed regimen is important to ensure the effectiveness and safety of the treatment. As with any medication, patient education on the proper application technique and expectations of therapy is crucial.
At Bayview Pharmacy, we understand the importance of personalized care and are committed to providing high-quality compounded medications tailored to the specific needs of our patients. Our team of knowledgeable compounding pharmacists is available to answer any questions and provide guidance on the use of Sirolimus 0.2% Topical Liquid. If you have any questions or require further information, please do not hesitate to reach out to us.
Sirolimus, also known as rapamycin, is an immunosuppressive agent that is primarily used to prevent organ transplant rejection and to treat certain rare lung diseases. When formulated as a 0.2% topical liquid, sirolimus is intended for direct application to the skin or mucosal surfaces. This localized treatment can be beneficial for conditions such as psoriasis, atopic dermatitis, and potentially for cutaneous manifestations of tuberous sclerosis complex, among others. The topical application aims to minimize systemic absorption and reduce the risk of systemic side effects.
Despite its localized use, it is important to consider potential drug interactions with sirolimus. Topical sirolimus may still have some degree of systemic absorption, especially when applied to large surface areas or to damaged skin. Therefore, interactions similar to those seen with oral sirolimus could potentially occur. Drugs that inhibit or induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) can affect sirolimus concentrations. Strong inhibitors of CYP3A4 and P-gp, such as ketoconazole, itraconazole, clarithromycin, and ritonavir, may increase sirolimus levels, potentially leading to toxicity. Conversely, inducers of CYP3A4 and P-gp, such as rifampin, carbamazepine, and St. John's Wort, may decrease sirolimus levels, reducing its efficacy.
Additionally, sirolimus has been shown to increase serum cholesterol and triglycerides, which may be a concern if used concomitantly with other drugs known to affect lipid metabolism. Patients should be monitored for changes in lipid profiles, and adjustments to lipid-lowering therapy may be necessary. Caution is also advised when using sirolimus with other drugs known to have nephrotoxic, hepatotoxic, or hematologic effects, as sirolimus can potentiate these adverse reactions.
Live vaccines should be avoided during treatment with sirolimus due to the potential for reduced efficacy of the vaccine and the risk of infection. Nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) may increase the risk of renal impairment when used with sirolimus and should be used with caution.
It is essential for patients and prescribers to be aware of all medications, supplements, and over-the-counter products the patient is using to identify potential interactions with topical sirolimus. Adjustments to therapy may be necessary, and in some cases, monitoring of sirolimus blood levels may be recommended, even though the topical route is associated with lower systemic exposure compared to oral administration.
For any questions or concerns regarding the use of sirolimus 0.2% topical liquid and potential drug interactions, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is available to provide guidance and support to ensure appropriate treatment for our patients.
Sirolimus, also known as rapamycin, is an immunosuppressant drug that is commonly used systemically to prevent organ transplant rejection. However, when formulated as a 0.2% topical liquid, sirolimus acts locally on the skin or mucosal surfaces. This formulation is designed to deliver the active ingredient directly to the affected area, minimizing systemic absorption and potential side effects associated with oral or intravenous administration.
The mechanism of action of sirolimus involves the inhibition of the mammalian target of rapamycin (mTOR) pathway, which is a crucial regulator of cell growth, proliferation, and survival. By inhibiting this pathway, sirolimus reduces the activity of certain cells and cytokines involved in the immune response and inflammation. This makes it particularly useful in treating diseases characterized by excessive immune or inflammatory responses, such as certain rare dermatological conditions or cutaneous manifestations of systemic diseases.
In the context of dermatology, sirolimus 0.2% topical liquid can be used to treat conditions such as psoriasis, atopic dermatitis, and cutaneous lupus erythematosus. It may also be beneficial in the management of vascular anomalies like Kaposi's sarcoma or angiofibromas associated with tuberous sclerosis complex. The topical application allows for a high concentration of the drug to be delivered to the affected area, providing therapeutic effects while reducing the risk of systemic side effects that can occur with oral sirolimus.
For patients and prescribers considering the use of sirolimus 0.2% topical liquid, it is important to understand that the effectiveness and safety profile of this formulation may vary based on individual patient characteristics and the specific condition being treated. It is also essential to apply the medication as directed, typically to clean, dry skin, and to avoid covering the treated area with occlusive dressings unless advised by a healthcare professional. Patients should be monitored for local skin reactions and any signs of systemic absorption, especially if the treatment area is extensive or if the skin barrier is compromised.
As compounding pharmacists at Bayview Pharmacy, we are committed to providing high-quality, customized medications to meet the unique needs of our patients. If you have any questions about sirolimus 0.2% topical liquid or its use in treating specific disease states, please do not hesitate to reach out to us. We are here to support both patients and prescribers with the information and guidance necessary to ensure appropriate treatment.
Sirolimus 0.2% Topical Liquid is typically used to treat certain skin conditions that may benefit from its immunosuppressive and anti-proliferative actions. This may include conditions like cutaneous angiofibromas, psoriasis, dermatitis, or specific rare skin disorders where sirolimus has shown therapeutic benefits.
This medication should be applied as directed by your healthcare provider. The general method involves gently cleaning and drying the area to be treated before using the dropper or application device to dispense a small amount of liquid, which is then spread thinly over the affected skin or mucosal surface.
It is generally not recommended to apply this medication to broken, wounded, or raw areas of the skin unless advised by a healthcare professional, as it could lead to irritation or increased absorption that might contribute to unwanted systemic effects.
Sirolimus 0.2% Topical Liquid may not be suitable for individuals with known hypersensitivity to sirolimus or any of the formulation’s components. It is also recommended to consult a healthcare provider before use if you are pregnant, planning to become pregnant, or breastfeeding.
Some individuals might experience side effects ranging from local irritation, redness, itching, or dryness at the application site. If you notice any severe reactions or systemic side effects like changes in your immune system or unusual bleeding or bruising, contact your healthcare provider immediately.
The frequency of application will depend on the individual’s condition and the directions provided by a healthcare provider. Follow the prescribed regimen, and do not alter the dosage without consulting your doctor.
While topical sirolimus is less likely to interact systemically compared to oral forms, it is still important to discuss all your current medications with your healthcare provider to avoid potential drug interactions.
If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
Store the medication in a cool and dry place, away from direct sunlight and heat. Keep the bottle tightly closed and out of reach of children and pets. Do not freeze the liquid unless specified by the manufacturer or your healthcare provider.
Avoid covering treated areas with occlusive dressings unless directed by your healthcare provider, as this may increase absorption. You should also avoid using other products on the treated area without prior consultation, including lotions, cosmetics, or other topical medications.
It is not advised to use Sirolimus 0.2% Topical Liquid for conditions other than those for which it was prescribed. The use of this medication should be specifically directed by a healthcare provider who is familiar with your medical history and current health status.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
